{
    "name": "interferon beta 1a",
    "comment": "Rx",
    "other_names": [
        "Avonex",
        "Rebif",
        "Rebif Rebidose",
        "AVOSTARTGRIP"
    ],
    "classes": [
        "Immunomodulators",
        "Multiple Sclerosis Treatments"
    ],
    "source": "https://reference.medscape.com/drug/avonex-rebif-interferon-beta-1a-343181",
    "pregnancy": {
        "common": [
            "Data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with use during early pregnancy",
            "Findings regarding a potential risk for low birth weight or miscarriage with use of interferon beta products in pregnancy have been inconsistent "
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In a study in pregnant monkeys, administration of interferon beta during pregnancy resulted in an increased rate of abortion at doses greater than those used clinically"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Limited published literature has described the presence of interferon beta-1a products in human milk at low levels; there are no data on effects of interferon beta-1a on milk production",
            "Therefore, developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to beta interferons, albumin (for albumin-containing formulations)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Flu-like symptoms may occur",
                "Efficacy in primary progressive MS not demonstrated conclusively; not recommended",
                "Anaphylaxis reported as a rare complication of therapy; other allergic reactions have included dyspnea, orolingual edema, skin rash, and urticaria; discontinue therapy if anaphylaxis or other allergic reactions occur",
                "Decreased peripheral blood counts in all cell lines, including rare pancytopenia and thrombocytopenia, reported from postmarketing experience in treated patients; in some cases, platelet counts were below10,000/microliter; some cases recurred with rechallenge; patients should be monitored for symptoms or signs of decreased blood counts",
                "Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported; cases have been reported several weeks to years after starting interferon beta products; discontinue therapy if clinical symptoms and laboratory findings consistent with TMA occur; manage as clinically indicated",
                "Seizures have been temporally associated with use of beta interferons in clinical trials and postmarketing safety surveillance; not known whether the events were related to the effects of multiple sclerosis alone, the drug, or to a combination of both",
                "Postmarketing reports of autoimmune disorders of multiple target organs in treated patients included idiopathic thrombocytopenia, hyper- and hypothyroidism, and rare cases of autoimmune hepatitis; if treated patients develop a new autoimmune disorder, consider stopping the therapy",
                "In addition to laboratory tests normally required for monitoring patients with multiple sclerosis, complete blood and differential white blood cell counts, platelet counts, and blood chemistries, including liver function tests, are recommended during therapy; patients with myelosuppression may require more intensive monitoring of complete blood cell counts, with differential and platelet counts",
                "Thyroid function should be monitored periodically If patients have or develop symptoms of thyroid dysfunction (hypo- or hyperthyroidism), thyroid function tests should be performed according to standard medical practice."
            ],
            "specific": [
                {
                    "type": "Depression and psychotic disorders",
                    "description": [
                        "Patients treated with this drug and their caregivers should be advised to report immediately any symptoms of depression, suicidal ideation, and/or psychosis to their prescribing physicians; if a patient develops depression or other severe psychiatric symptoms, cessation of this therapy should be considered",
                        "There have been postmarketing reports of depression, suicidal ideation, and/or development of new or worsening other pre-existing psychiatric disorders, including psychosis; for some of these patients, symptoms of depression improved upon cessation of therapy"
                    ]
                },
                {
                    "type": "Hepatic injury",
                    "description": [
                        "Severe hepatic injury, including cases of hepatic failure, has been reported rarely with this medication; asymptomatic elevation of hepatic transaminases has also been reported, and in some patients has recurred upon rechallenge with this drug; in some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury",
                        "The potential risk of this drug used in combination with known hepatotoxic drugs or other products (eg, alcohol) should be considered prior to starting therapy, or before starting hepatotoxic drugs; patients should be monitored for signs of hepatic injury"
                    ]
                },
                {
                    "type": "Congestive heart failure",
                    "description": [
                        "Patients with pre-existing congestive heart failure should be monitored for worsening of their cardiac condition during initiation of and continued therapy",
                        "While beta interferons do not have any known direct cardiac toxicity, during the postmarketing period cases of congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure have been reported in patients without known predisposition to these events, and without other etiologies being established",
                        "In some cases, these events have been temporally related to the administration of therapy; In some of these instances recurrence upon rechallenge was observed"
                    ]
                },
                {
                    "type": "Injection site reactions",
                    "description": [
                        "Injection site reactions, including injection site necrosis, can occur with the use of interferon beta products; in controlled clinical trials, injection site reactions (eg, injection site pain, bruising, or erythema) reported; reactions included injection site inflammation (6%), injection site pain (8%), injection site mass (<1%), nonspecific reactions",
                        "Injection site abscesses and cellulitis and injection site necrosis reported in postmarketing setting with interferon beta products; some cases required treatment with hospitalization for surgical drainage and intravenous antibiotics",
                        "Periodically evaluate patient understanding and use of aseptic self-injection techniques and procedures, particularly if injection site necrosis has occurred",
                        "Whether to discontinue therapy following a single site of necrosis is dependent on extent of necrosis; for patients who continue therapy after injection site necrosis has occurred, avoid administration of the drug into the affected area until it is fully healed; if multiple lesions occur, change injection site or discontinue therapy until healing occurs"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "interferon beta 1a, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "interferon beta 1a, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "interferon beta 1a, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, interferon beta 1a.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "interferon beta 1a, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "interferon beta 1a, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "interferon beta 1a and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "interferon beta 1a, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, interferon beta 1a.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "interferon beta 1a, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, interferon beta 1a.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ansofaxine",
            "description": {
                "common": "ansofaxine, interferon beta 1a.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "interferon beta 1a, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Cutaneous vasculitic toxicities (eg, vasculitic ulcerations and gangrene) were reported during therapy with hydroxyurea in patients with a history of, or currently receiving, interferon therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, interferon beta 1a.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Ifosfamide may enhance the toxicities of myelosuppressive agents. Monitor for increased risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "interferon beta 1a and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine, interferon beta 1a.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod, interferon beta 1a.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and interferon beta 1a both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immune effects during such therapy and in the weeks following administration. Siponimod can generally be started immediately after discontinuation of beta interferon."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and interferon beta 1a both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and interferon beta 1a both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "interferon beta 1a increases levels of zidovudine by decreasing renal clearance. Use Caution/Monitor. Interferons may enhance potential for adverse effects. Patients should be monitored for signs and symptoms of increased myelosuppression and liver decompensation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "natalizumab",
            "description": {
                "common": "interferon beta 1a increases levels of natalizumab by decreasing renal clearance. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Injection site reactions",
            "percent": "83"
        },
        {
            "name": "Rebif",
            "percent": "28"
        },
        {
            "name": "Avonex",
            "percent": "67"
        },
        {
            "name": "Headache",
            "percent": "61"
        },
        {
            "name": "Flu",
            "percent": "34"
        },
        {
            "name": "like syndrome",
            "percent": "33"
        },
        {
            "name": "Muscle ache",
            "percent": "14"
        },
        {
            "name": "Nausea",
            "percent": "24"
        },
        {
            "name": "URT infection",
            "percent": "23"
        },
        {
            "name": "Pain",
            "percent": "21"
        },
        {
            "name": "Fever",
            "percent": "16"
        },
        {
            "name": "Asthenia",
            "percent": "15"
        },
        {
            "name": "Diarrhea",
            "percent": "11"
        },
        {
            "name": "Dizziness",
            "percent": "11"
        },
        {
            "name": "Infection",
            "percent": "9"
        },
        {
            "name": "Dyspepsia",
            "percent": "8"
        },
        {
            "name": "Abdominal pain",
            "percent": "6"
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "Aggravation of seizure disorders",
            "percent": null
        },
        {
            "name": "Autoimmune disorders",
            "percent": null
        },
        {
            "name": "Drug",
            "percent": null
        },
        {
            "name": "induced lupus erythematosus",
            "percent": null
        },
        {
            "name": "autoimmune hepatitis",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Thrombotic thrombocytopenic purpura",
            "percent": null
        },
        {
            "name": "hemolytic uremic syndrome",
            "percent": null
        },
        {
            "name": "TTP",
            "percent": null
        },
        {
            "name": "HUS",
            "percent": null
        },
        {
            "name": "hemolytic anemia",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Retinal vascular disorders",
            "percent": null
        },
        {
            "name": "ie",
            "percent": null
        },
        {
            "name": "retinopathy",
            "percent": null
        },
        {
            "name": "cotton wool spots or obstruction of retinal artery or vein",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "Hyperhidrosis",
            "percent": null
        },
        {
            "name": "Injection site reactions including necrosis",
            "percent": null
        }
    ]
}